Lymphoma | What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma
Featuring an interview with Dr Gilles Salles, including the following topics: Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00) Natural history of FL and current treatment landscape in the first-line setting (5:20) Testing approaches for the detection of EZH2 mutations (14:37) Mechanism of action of the EZH inhibitors tazemetostat and valemetostat (18:31) Tazemetostat monotherapy as treatment for relapsed/refractory FL (20:58) Ongoing evaluation of novel treatment approaches with tazemetostat for FL and other lymphomas (25:31) Approved indications for tazemetostat for wild-type FL and FL with EZH2 mutations; sequencing of tazemetostat with bispecific antibodies and CAR T-cell therapy (34:07) Available clinical data with the novel dual EZH1/EZH2 inhibitor valemetostat (42:37) Personal experience with CAR T-cell therapy and perspectives on possible underlying reasons for the development of T-cell lymphoma in patients receiving this treatment (44:35) Management of FL in patients who experience relapse within 24 months of receiving treatment (POD24) (48:25) Myths or misperceptions associated with tazemetostat and other therapies approved in the relapsed FL setting (52:15) Perspectives on the future treatment landscape of FL (54:29) CME information and select publications